Eli Lilly and Company announced results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet), the first and only trial of its… read more.
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the… read more.
In patients diagnosed with grade 2 IDH-mutant glioma, treatment with investigative vorasidenib has significantly improved progression-free survival. The findings were published on June 5, 2023 in the NEJM/New… read more.
TG Therapeutics announced that the European Commission (EC) has granted approval of Briumvi (ublituximab xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)… read more.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.
Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the… read more.
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher… read more.
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
Even mild concussion can cause long-lasting effects to the brain, according to researchers at the University of Cambridge. Using data from a Europe-wide study, the team has shown… read more.
Researchers at UNSW Sydney and Neuroscience Research Australia (NeuRA) have developed and evaluated a tool for assessing dementia risk, with promising initial results. Currently, over 55 million people are living with dementia… read more.
Exenatide, an injectable treatment for type 2 diabetes, has shown efficacy for the treatment of ‘blinding’ headaches known as idiopathic intercranial hypertension (IIH). Researchers from a phase 2… read more.
People who have low bone density may have an increased risk of developing dementia compared to people who have higher bone density, according to a study published in… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
